Details:
Through the license agreement, Merck will gain global rights to develop and commercialize MK-5684 (opevesostat), which is being evaluated for metastatic castration-resistant prostate cancer.
Lead Product(s): Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area: Oncology Product Name: MK-5684
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $1,920.0 million Upfront Cash: $290.0 million
Deal Type: Licensing Agreement July 01, 2024
Details:
Under the license agreement, Tenax will be developing and commercializing the TNX-103 (levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction.
Lead Product(s): Levosimendan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TNX-103
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Tenax Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 20, 2024
Details:
The net proceeds will be used to advance Lego's ADC pipeline including, LCB14, an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2).
Lead Product(s): LCB14
Therapeutic Area: Oncology Product Name: LCB14
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: LegoChem Biosciences
Deal Size: $410.9 million Upfront Cash: Undisclosed
Deal Type: Financing January 16, 2024
Details:
Under the agreement, Orion gains access to Glykos’ proprietary ADC technologies, initiating an ADC program and will be responsible for the target selection, research, development, and commercialization of up to three next-generation ADCs, with a focus on solid tumors.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Glykos
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2024
Details:
ODM-208/MK5684 is an investigational CYP11A1 inhibitor, which is being evaluated in combination with hormone replacement therapy under phase 3 clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Lead Product(s): MK5684,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area: Oncology Product Name: ODM-208
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Details:
ODM-208 (or MK-5684) is an investigational oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as metastatic castration-resistant prostate cancer.
Lead Product(s): MK-5684,Dexamethasone,Hydrocortisone
Therapeutic Area: Oncology Product Name: ODM-208
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
The agreement aims for the exclusive right to package, distribute, market and sell Suvexx, a patent protected, fixed dose combination of naproxen sodium and sumatriptan approved for the acute treatment of migraine attacks in adults, in all remaining E.U. countries.
Lead Product(s): Naproxen Sodium,Sumatriptan
Therapeutic Area: Neurology Product Name: Suvexx
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Nuvo Pharmaceuticals
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 15, 2023
Details:
Ztalmy (ganaxolone) is a positive allosteric modulation of the gamma-aminobutyric acid type A (GABAA) receptor in the CNS. It is used for the treatment of epileptic seizures associated with CDKL5 deficiency disorder.
Lead Product(s): Ganaxolone
Therapeutic Area: Genetic Disease Product Name: Ztalmy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Marinus Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Details:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023